Physicians should encourage pharmaceutical companies to make socially responsible funding decisions and take an active role in setting biomedical research priorities by advocating for fair and effective allocations of public and private biomedical R & D investments.
A Canadian physician reports there is systematic bias to the outcome of published research funded by the pharmaceutical industry and believes more steps need to be taken to improve the integrity of clinical research reports in the United States and Canada.
The history of the AMA's policy on anencephalic newborns as organ donors is a living example of what medical science can do sometimes conflicts with society's support or nonsupport of those possibilities.
A centralized registry to provide information to consumers regarding the effectiveness of clinical trials is needed to help patients make informed decisions about treatment.
An ethical case explores a lawsuit against Fred Hutchinson Cancer Center of Seattle by patients who claimed they were not told of the full risks associated with a clinical trial they participated in.